You are here

  • Home
  • Archive
  • Volume 29, Issue 3
  • Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous non–small-cell lung cancer in China

Article metrics

Article menu
Download PDFPDF
Original research
Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous non–small-cell lung cancer in China

 

Online download statistics by month:

Online download statistics by month: July 2020 to March 2024

AbstractFullPdf
Jul 20205620
Aug 20207641113
Sep 202030455
Oct 202028111
Nov 2020219119
Dec 202025073
Jan 202129993
Feb 202126154
Mar 202120875
Apr 202120236
May 20217144
Jun 2021655
Jul 2021873
Aug 2021440
Sep 2021878
Oct 202127471
Nov 202138321
Dec 202139233
Jan 202225690
Feb 202229410
Mar 202228000
Apr 202258764
May 202264185
Jun 2022513113
Jul 202218372
Aug 202218664
Sep 2022281116
Oct 2022215104
Nov 202218670
Dec 202228444
Jan 202312232
Feb 202322222
Mar 202315330
Apr 202315751
May 20238421
Jun 202313200
Jul 20238952
Aug 20239801
Sep 20236330
Oct 20238031
Nov 202310420
Dec 202312500
Jan 202411694
Feb 202410622
Mar 2024172108
Total9719229130